Price Alert

Astellas Pharma Inc. (ALPMF)

OTC: ALPMF · Real-Time Price · USD

11.10

0.00 (0.00%)

At close: Aug 08, 2025, 2:03 PM

Astellas Pharma Income Statement

Financials in JPY. Fiscal year is April - March.

Fiscal Year	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020
Revenue	459.29B	517.41B	462.5B	473.12B	414.6B	421.93B	392.15B	374.99B	354.25B	402.18B	380.39B	381.79B	303.87B	340.63B	325.52B	326.14B	308.62B	325.43B	308.51B	306.97B
Cost of Revenue	76.86B	98.52B	82.69B	91.14B	105.88B	75.9B	74.41B	68.95B	62.28B	74.42B	62.78B	88.87B	58.91B	69.36B	62.5B	62.23B	58.33B	68.19B	59.9B	59.65B
Gross Profit	382.44B	418.88B	379.81B	381.99B	308.73B	346.04B	317.74B	306.04B	291.97B	327.76B	317.61B	292.92B	244.96B	271.27B	263.02B	263.91B	250.29B	257.24B	248.62B	247.31B
Operating Income	63.52B	-116.19B	63.17B	50.66B	37.72B	18.96B	5.22B	45.79B	-48.25B	61.39B	86.74B	33.15B	-13.69B	79.2B	54.08B	36.09B	-23.42B	72.6B	26.06B	60.81B
Interest Income	n/a	n/a	n/a	4.33B	4.12B	1.18B	2.37B	3.78B	2.44B	1.17B	3.56B	927M	3.84B	417M	432M	1.46B	5.1B	3.06B	3.07B	379M
Pretax Income	60.55B	-118.36B	38.55B	50.49B	-45.96B	17.31B	5.33B	46.85B	-47.88B	59.76B	88.8B	31.68B	-10.52B	78.32B	53.26B	35.83B	-18.9B	75.14B	28.85B	60.24B
Net Income	74.9B	-97.66B	35.91B	37.6B	-33.28B	14.51B	-1.46B	33.13B	-46.13B	48.41B	71.62B	24.81B	-8.41B	60.88B	40.92B	30.69B	-12.33B	60.08B	22.43B	50.41B
Selling & General & Admin	211.32B	225.31B	199.53B	206.88B	193.15B	199.5B	179.28B	168.18B	159.29B	163.02B	154.56B	153.4B	142.42B	135.91B	133.4B	137.11B	141.27B	120.91B	121.36B	120.78B
Research & Development	76.23B	79.09B	85.51B	86.82B	77.85B	74.39B	77.36B	64.59B	70.08B	66.88B	65.17B	74.01B	68.36B	58.59B	60.75B	58.31B	55.67B	57.12B	54.41B	57.29B
Other Expenses	31.37B	230.68B	31.6B	37.63B	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Expenses	318.92B	535.08B	316.64B	331.33B	271B	327.17B	320.95B	260.99B	340.12B	266B	232.3B	260.29B	257.2B	217.92B	208.96B	228.12B	274.46B	184.65B	222.31B	186.47B
Interest Expense	n/a	n/a	n/a	4.5B	4.19B	2.83B	2.27B	2.72B	2.07B	2.8B	1.51B	2.4B	675M	1.3B	1.25B	1.72B	589M	520M	271M	956M
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	395.77B	633.6B	399.33B	422.47B	376.88B	403.06B	395.37B	329.94B	402.4B	340.42B	295.08B	349.16B	316.12B	287.28B	271.46B	290.35B	332.78B	252.83B	282.21B	246.13B
Income Tax Expense	-14.34B	-20.7B	2.64B	12.89B	-15.38B	2.8B	6.79B	13.72B	-1.75B	11.35B	17.18B	6.87B	-2.11B	17.43B	12.33B	5.14B	-6.58B	15.06B	6.43B	9.82B
Shares Outstanding (Basic)	1.82B	1.79B	1.8B	1.8B	1.79B	1.79B	1.79B	1.79B	1.81B	1.82B	1.82B	1.83B	1.84B	1.85B	1.85B	1.85B	1.86B	1.86B	1.86B	1.86B
Shares Outstanding (Diluted)	1.82B	1.79B	1.8B	1.8B	1.79B	1.8B	1.79B	1.8B	1.81B	1.82B	1.82B	1.83B	1.84B	1.85B	1.85B	1.85B	1.86B	1.86B	1.86B	1.86B
EPS (Basic)	41.83	-54.57	20.06	20.94	-18.56	8.09	-0.81	18.46	-25.49	26.56	39.30	13.60	-4.57	32.86	22.09	16.56	-6.64	32.34	12.07	27.14
EPS (Diluted)	41.19	-54.57	19.97	20.94	-18.56	8.06	-0.81	18.42	-25.49	26.55	39.28	13.59	-4.57	32.84	22.08	16.55	-6.64	32.33	12.07	27.12
EBITDA	101.78B	126.06B	88.05B	103.59B	86.37B	65.85B	39.89B	68.3B	-22.79B	84.75B	108.16B	69.5B	11.24B	74.87B	73B	53.94B	248M	90.74B	44.24B	78.84B
EBIT	54.1B	74.89B	38.03B	53.32B	-44.48B	20.14B	7.6B	49.57B	-45.8B	62.56B	90.31B	34.08B	-9.84B	79.62B	54.51B	37.55B	-18.31B	75.66B	29.12B	61.19B
Depreciation & Amortization	47.68B	51.16B	50.02B	50.27B	48.64B	46.98B	38.97B	23.24B	23.02B	23B	22.85B	36.87B	21.08B	21.52B	18.94B	18.14B	18.56B	18.15B	17.94B	18B